V. Wagner

发表

Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab

B. Barber, P. Wang, S. Long, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

S. Severi, O. Sartor, G. Procopio, 2019, The Prostate.

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects

P. Vlachos, T. Mant, V. Wagner, 2016, British journal of clinical pharmacology.

Effects of bortezomib on pro‐inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman Disease

C. Heussel, C. Huber, G. Hess, 2006, British journal of haematology.

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.

F. Saad, C. Sternberg, R. Epstein, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

F. Saad, C. Parker, M. Teufel, 2019, The Lancet. Oncology.

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

C. Higano, D. Petrylak, O. Sartor, 2021, ESMO open.

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Xingdang Liu, F. Zhou, Rui Li, 2020, Asia-Pacific journal of clinical oncology.

Surgery, radiation, and systemic therapies in patients with metastatic melanoma.

B. Barber, Zhongyun Zhao, V. Wagner, 2012 .

Targeted thorium-227 conjugates as treatment options in oncology

J. Karlsson, S. Hammer, A. Cuthbertson, 2023, Frontiers in Medicine.

Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

K. Fizazi, I. Skoneczna, H. Krissel, 2021 .

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

S. Severi, O. Sartor, G. Procopio, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, C. Parker, Q. Ng, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

EFFICACY AND SAFETY OF RADIUM‐223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL: PD24‐07

C. Parker, L. Klotz, A. Dicker, 2017 .